This is the same data as in 'pancreatic', with overall and progression-free survival calculated. Dates have been removed.
A data frame with 41 observations on the following 4 variables.
Progression-free survival: Time from entry until disease progression. If no progression was observed, before death, the time to death is used.
Overall survival: Time from entry until death
This censoring indicator is 1 for all patients, since all patients died.
a factor with levels
LA (locally advanced) or
Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012) A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointestinal Cancer Research 5, 77 - 83.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.